HSK 42360
Alternative Names: HSK-42360Latest Information Update: 26 Sep 2025
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein b-raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Brain cancer; Solid tumours
Most Recent Events
- 26 Sep 2025 Efficacy and adverse events data from a phase I trial in Solid tumours presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 15 Aug 2025 Phase-I clinical trials in Brain cancer (In adolescents, In children, Second-line therapy or greater) in China (PO) (NCT07158710)
- 25 Jun 2024 Phase-I clinical trials in Cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Monotherapy) in China (PO) (NCT06536400)